Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAFV600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison

D. Planchard; J. Mazières; J.M. Grouin; C. Le Reun; H. Luttenauer; M. Boussahoua; B. Macabeo

doi:10.1016/j.esmoop.2025.106051

January 27, 2026ESMO OpenOpen Access

Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAFV600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison

View Full Paper

Ask AI

Bookmark

Share

Key Points

Encorafenib plus binimetinib (E + B) resulted in longer progression-free survival compared to dabrafenib plus trametinib (D + T), indicating effectiveness.
The treatment with E + B was associated with fewer serious adverse events, enhancing its safety profile.
This analysis employed a matching-adjusted indirect treatment comparison to evaluate the two regimens effectively.
The findings support considering E + B as a promising first-line treatment option for patients with BRAF V600E-mutant metastatic non-small cell lung cancer.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Analysis demonstrates improved progression-free survival with encorafenib plus binimetinib in BRAF V600E-mutant lung cancer, suggesting a viable treatment alternative.

Abstract

This analysis suggests that E + B was associated with statistically significantly longer PFS and fewer SAEs compared with D + T, and may offer an alternative option for the 1L treatment of BRAFV600E-mutant metastatic non-small cell lung cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Planchard et al. (2026) studied this question.

synapsesocial.com/papers/69a75b24c6e9836116a21eab https://doi.org/10.1016/j.esmoop.2025.106051

View Full Paper

Ask AI

Bookmark

Share

Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAFV600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAFV600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading